What Apotex does

Apotex is a Canadian-headquartered global pharmaceutical company founded in 1974 by Dr. Barry Sherman, operating across four business segments: generics (approximately 460 products distributed across ~70 countries), biosimilars (via the Apobiologix subsidiary), innovative and specialty branded medicines (via Searchlight Pharma), and consumer health products (via the CanPrev acquisition). The company operates six world-class manufacturing sites across Canada, the United States, Mexico, and India with a combined production capacity of 14-25 billion finished doses annually. Its vertically integrated model includes in-house API manufacturing, oral solid dose, sterile injectable, nasal spray, ophthalmic, and topical formulation capabilities, with complex peptide manufacturing (semaglutide) and biosimilar development representing its highest technical differentiators.

The company's revenue model centers on one-time sales of generic pharmaceuticals priced at approximately one-third of branded equivalents, complemented by licensing royalties on specialty branded products (Nebido, Qutenza, Linzagolix, LOQTORZI) and consumer health margins. Apotex employs a hybrid go-to-market combining direct sales to hospitals and pharmacy chains, a 16,000+ distribution partner network, and emerging telehealth channels (Felix Health, Hims & Hers). For fiscal year ended March 31, 2026, the company reported revenue of C$3.5 billion and net income of C$374 million, with specialty drugs and biosimilars now comprising 49% of revenue at 15% annual growth.

In June 2026, Apotex completed its IPO on the Toronto Stock Exchange under ticker APTX, raising C$1.495 billion at a C$5.87 billion post-money valuation, marking the largest TSX listing in five years. SK Capital Partners, which acquired the company from the Sherman estate in 2023, retained a controlling 52.4% stake. The company is led by CEO Jeff Watson (appointed March 2026) and is pursuing a strategic pivot from low-margin generics toward higher-margin specialty pharmaceuticals, biosimilars, and consumer health, evidenced by recent major launches (Apo-Semaglutide, DENOZA biosimilar, LOQTORZI) and acquisitions (Searchlight, CanPrev, Cumberland Pharmaceuticals).

Name

Apotex

Legal name

Apotex Inc.

Website

http://www.apotex.com

Company type

Public

Founded year

1974

Operating status

Ipo

Headcount range

5,001–10,000 employees

Short description

Apotex is a Canadian-headquartered global pharmaceutical company that develops, manufactures, and distributes generic drugs, biosimilars, specialty branded medicines, and consumer health products across approximately 70 countries through six manufacturing sites and 16,000+ distribution partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Food And Kindred Products (2000)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Specialty branded drugs
• Consumer health products
• Pharmaceutical manufacturing

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Core revenue stream from manufacturing and selling generic versions of branded pharmaceuticals. Apotex is the leader in Canadian generics and top 5 in the US, with approximately 460 generic products distributed across ~70 countries. Products include oral solid doses, injectables, nasal sprays, ophthalmic solutions, and topical formulations.
2. Biosimilars: Growing revenue stream from biosimilar products including DENOZA (denosumab), Aflivu (aflibercept), and oncology biosimilars through Apobiologix. Specialty drugs and biosimilars now comprise 49% of revenues with 15% annual growth since 2023.
3. Innovative/Specialty Branded Pharmaceuticals: Revenue from branded specialty pharmaceuticals through Searchlight Pharma division, including licensed products like LOQTORZI (toripalimab), Nebido, Qutenza, and linzagolix. Apotex has over 100 branded and biosimilar products.
4. Consumer Health Products: Revenue from vitamins, supplements, and natural health products through acquired brand CanPrev (including CanPrev, Cyto-Matrix, and Orange Naturals brands), distributed across over 3,400 retail locations in Canada.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels6 records

Core offering

Apotex is a vertically integrated pharmaceutical manufacturer that develops, produces, and sells approximately 460 generic pharmaceutical products, biosimilars, innovative/specialty branded medicines, and consumer health products across approximately 70 countries. The company operates four portfolio pillars: generics (oral solids, injectables, nasal sprays, ophthalmic solutions, topicals), biosimilars (oncology and bone health through Apobiologix), specialty branded pharmaceuticals (through Searchlight Pharma), and consumer health (vitamins and supplements through CanPrev brands). Manufacturing occurs at six cGMP-compliant facilities in Canada, the US, Mexico, and India, with annual capacity of 14-25 billion doses.

Product overview

Apotex is a Canadian-based global pharmaceutical company offering a diversified portfolio of generic pharmaceuticals, biosimilars, innovative/specialty branded medicines, and consumer health products. The company operates across four main segments: (1) Generics - approximately 460 generic products across ~70 countries including oral solids, injectables, and specialty formulations; (2) Biosimilars through Apobiologix - Grastofil, Lapelga, Bambevi, and toripalimab (LOQTORZI); (3) Innovative & Specialty Medicines through Searchlight Pharma - branded products including LOQTORZI for nasopharyngeal cancer, Nebido testosterone therapy, Qutenza pain patch, Linzagolix for uterine fibroids; (4) Consumer Health through CanPrev acquisition - vitamins, supplements, and natural health products under CanPrev, Cyto-Matrix, and Orange Naturals brands. Key recent launches include Apo-Semaglutide generic Ozempic, DENOZA denosumab biosimilar, Aflivu aflibercept biosimilar, and various FDA-approved generics.

Differentiator

Problem solved

Functional benefit

Brands

• Apobiologix: Biosimilar development subsidiary creating pathways to affordable biologic treatments through innovation, development, and partnerships in oncology and emerging therapeutic areas.
• Searchlight Pharma
• CanPrev
• Cyto-Matrix
• Orange Naturals

Products and services

• Apo-Semaglutide Injection Generic equivalent of Ozempic (semaglutide injection) approved by Health Canada for once-weekly treatment of type 2 diabetes in adults, available in 2mg and 4mg prefilled pen formats and priced at approximately one-third the cost of branded Ozempic.
• DENOZA Biosimilar referencing Amgen's Prolia (denosumab injection) approved by Health Canada for treatment of osteoporosis in postmenopausal women and men at high fracture risk, available in prefilled syringe format.
• Aflivu Biosimilar to Eylea (aflibercept) approved by Health Canada for treatment of neovascular age-related macular degeneration and other retinal diseases, available in pre-filled syringe and vial formats.
• LOQTORZI Toripalimab immuno-therapy approved by Health Canada for recurrent unresectable or metastatic nasopharyngeal carcinoma, used with chemotherapy or as monotherapy; Apotex's first novel biologic therapy, licensed from Coherus BioSciences.
• CLOBIVIS Clobetasol propionate ophthalmic suspension 0.05% approved by Health Canada for treatment of postoperative inflammation and pain following cataract surgery, using nanoparticle technology licensed from Formosa.
• Nebido Long-acting injectable testosterone replacement therapy (testosterone undecanoate) for male hypogonadism, licensed from Grünenthal for the Canadian market and marketed by Searchlight Pharma.
• Qutenza Topical non-systemic, non-opioid pain patch for neuropathic pain management, licensed from Grünenthal for the Canadian market and marketed by Searchlight Pharma.
• Linzagolix Once-daily oral GnRH antagonist treatment for uterine fibroids, developed by Kissei Pharmaceutical and licensed for the Canadian market through Searchlight Pharma.
• Nilotinib Capsules Generic version of Novartis' Tasigna (nilotinib) for treatment of Philadelphia chromosome positive chronic myeloid leukemia, with 180 days of US market exclusivity as a first generic.
• Generic Infuvite Pediatric Injection Generic multivitamin injectable for pediatric parenteral nutrition, eligible for 180-day CGT exclusivity for single-dose vial, developed in partnership with Orbicular Pharmaceutical Technologies and Gland Pharma.
• Generic Infuvite Adult Injection Generic multivitamin injectable for adult parenteral nutrition, available in single dose and pharmacy bulk package formats, developed in partnership with Orbicular Pharmaceutical Technologies and Gland Pharma.
• Nintedanib Soft Gel Capsules Generic version of Ofev (nintedanib) for treatment of pulmonary fibrosis, available in 100mg and 150mg strengths, developed in collaboration with DifGen Pharmaceuticals.
• Apobiologix Biosimilars (Grastofil, Lapelga, Bambevi) Portfolio of oncology biosimilars including Grastofil (filgrastim), Lapelga (pegfilgrastim), and Bambevi (bevacizumab), part of the Apobiologix division and among the top-selling biosimilars in Canada for oncology supportive care and treatment.
• CanPrev Consumer Health Brand Premium vitamins, supplements, and natural health products brand under CanPrev (with sub-brands Cyto-Matrix and Orange Naturals), designed by licensed health practitioners and distributed through 3,400+ retail locations in Canada including health food stores, naturopathic channels, and grocery retail.

Quantifiable outcome

• Specialty drugs and biosimilars now comprise 49% of revenues with 15% annual growth since 2023
• +3 more outcomes

Named customers5 records

Segments7 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered major, core and minor.

• Felix HealthmajorChannel Partner/ Reseller/ Distributor · 28 May 2026Felix Health, Canada's largest virtual weight-loss clinic, offers Apotex's Apo-Semaglutide at $149/month with free delivery and clinical support. Felix saw demand surge to approximately 14x typical daily volumes within 24 hours of launch.
• Hims & Hers HealthmajorChannel Partner/ Reseller/ Distributor · 27 May 2026Hims & Hers Health launched generic semaglutide in Canada through supplier Apotex, expanding their weight-loss offering. The telehealth company also announced a $350 million convertible notes offering to fund international expansion.
• OneSource Specialty PharmacoreTechnology or Integration · 4 May 2026OneSource Specialty Pharma provided end-to-end manufacturing from its FDA-approved facility in Bengaluru, India. The company manufactures the semaglutide active pharmaceutical ingredient entirely in-house with finished product production handled by OneSource.
• Orbicular Pharmaceutical TechnologiescoreStrategic or Co-development Partner · 1 May 2026Partnership for development and manufacturing of generic semaglutide injection (generic Ozempic/Apo-Semaglutide). Apotex received Health Canada approval for Apo-Semaglutide on May 1, 2026, marking the first Canadian-based company to gain such authorization. The product was developed in partnership with Orbicular with manufacturing by OneSource Specialty Pharma in Bengaluru.
• Cumberland PharmaceuticalscoreStrategic or Co-development Partner · 23 April 2026Strategic transaction where Apotex will acquire Cumberland's portfolio of FDA-approved brands for $100 million in cash. Products include Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, Vaprisol, and Talicia across acute care, oncology, infectious disease, and gastroenterology. Transaction pending Cumberland shareholder approval.
• Halo PharmaceuticalsmajorTechnology or Integration · 14 April 2026Strategic sterile filling partnership providing Apotex access to significant sterile injectable filling capacity at Halo's Whippany, New Jersey facility. Includes vial and pre-filled syringe filling capabilities, supporting Apotex's U.S.-based manufacturing strategy and sterile injectables network.
• Gland PharmacoreTechnology or Integration · 14 April 2026Partnership with Orbicular Pharmaceutical Technologies and Gland Pharma for FDA approval of generic Infuvite Adult and Pediatric Injection. The pediatric approval received 180-day CGT exclusivity for single-dose vial. Apotex serves as the ANDA sponsor leading US commercialization.
• FormosaminorOEM/ Whitelabel/ Licensing Partner · 25 March 2026Licensing of CLOBIVIS (clobetasol propionate ophthalmic suspension 0.05%) from Formosa for postoperative inflammation and pain following cataract surgery. Product uses nanoparticle technology.
• GrünenthalcoreOEM/ Whitelabel/ Licensing Partner · 5 February 2026Licensing agreement granting Apotex exclusive Canadian rights to Nebido (testosterone undecanoate), a long-acting injectable therapy for male hypogonadism. Apotex's Searchlight Pharma division will pursue regulatory approval and market the product in Canada. Grünenthal receives upfront payment, regulatory milestone payments, and margin on sales.
• Coherus BioSciencescoreOEM/ Whitelabel/ Licensing Partner · 23 October 2025Licensing agreement securing Canadian rights to LOQTORZI (toripalimab), the first and only Health Canada-approved immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer. This marks Apotex's first novel biologic therapy launch, representing strategic expansion into oncology.
• Kissei PharmaceuticalmajorOEM/ Whitelabel/ Licensing Partner · 7 October 2025Licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral GnRH antagonist treatment for uterine fibroids developed by Kissei Pharmaceutical. Searchlight Pharma will lead regulatory efforts to pursue marketing authorization in Canada.
• GrünenthalcoreOEM/ Whitelabel/ Licensing Partner · 24 February 2025Licensing agreement granting Apotex exclusive Canadian rights to Qutenza, a topical non-systemic, non-opioid pain patch for neuropathic pain management. Apotex's Searchlight Pharma division will pursue regulatory approval and market the product in Canada.
• Searchlight Pharma Inc.coreStrategic or Co-development Partner · 2 April 2024Apotex acquired Searchlight Pharma, a Canadian specialty innovative branded pharmaceutical company, for an estimated value of over $500 million in June 2024. Searchlight focuses on licensed, patented drugs and recent acquisitions, operating predominantly in Canada. This acquisition enhances Apotex's position in the innovative branded pharmaceutical market and diversifies its portfolio, marking a strategic expansion coinciding with Apotex's 50th anniversary.

Scale indicators15 records

Recent moves6 records

Expansion highlights2 records

Direct peers

• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with a large specialty and biosimilars portfolio; the most direct competitor to Apotex in North American generics, complex generics, and biosimilars across the same therapeutic areas.
• Sandoz (Novartis): World's largest generics and biosimilars company with strong North American and European presence; competes head-on with Apotex in generic OSDs, sterile injectables, and biosimilars such as denosumab and aflibercept.
• Viatris: Global generics and specialty player formed from Mylan and Pfizer's Upjohn; competes with Apotex in generic OSDs, sterile injectables, and is a direct peer for complex generics and biosimilars in Canada and the US.
• Sun Pharmaceutical Industries: India-based global specialty generics company with strong US presence; comparable to Apotex as a vertically integrated generic manufacturer competing in dermatology, ophthalmology, and complex generics including specialty injectables.
• Lupin Pharmaceuticals: India-headquartered global generic manufacturer with strong US business; competes with Apotex in generic OSDs, complex generics, and specialty segments like women's health and ophthalmology.
• Aurobindo Pharma: Large vertically integrated Indian generic manufacturer with global reach including North America; competes with Apotex in oral solid doses, injectables, and increasingly in specialty and biosimilars.
• Dr. Reddy's Laboratories: India-based global generics and biosimilars player with significant North American commercial operations; directly comparable to Apotex in generic injectables, OSDs, and biosimilars strategy.
• Hikma Pharmaceuticals: Global generic and specialty pharmaceutical company with strong US injectable franchise and MENA footprint; comparable to Apotex in sterile injectables, generics, and specialty branded products.

Broad incumbents

• Endo International: Specialty and generics pharmaceutical company with focus on sterile injectables and specialty therapeutics; broader US-focused competitor that overlaps with Apotex in sterile injectable generics and specialty.

Emerging players

• Biocon Biologics: India-headquartered biosimilars pure-play with growing North American presence; comparable to Apotex's Apobiologix division as a focused biosimilar developer targeting oncology, immunology, and metabolic disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/apotex
• LinkedInlinkedin.com/company/7989

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apotex